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Abstract
Background and Objective In patients with atrial fibrillation following percutaneous coronary intervention, if a proton pump 
inhibitor is used, could that allow the use of warfarin triple therapy, or is there additional reduction in bleeding while using 
it with dual therapy?
Methods The RE-DUAL PCI trial randomized 2725 patients with atrial fibrillation post-percutaneous coronary intervention 
to dabigatran dual therapy (110 or 150 mg twice daily, with clopidogrel or ticagrelor) or warfarin triple therapy (with clopi-
dogrel or ticagrelor, and aspirin for 1–3 months). This prespecified subgroup analysis evaluated risks of a first major bleeding 
event or clinically relevant non-major bleeding event, all gastrointestinal bleeding, and a composite efficacy endpoint of all-
cause mortality/thromboembolic event or unplanned revascularization according to baseline use of a proton pump inhibitor.
Results Of 2678 analyzed patients, 1641 (61.3%) were receiving a proton pump inhibitor at baseline. Dabigatran 110 and 
150 mg dual therapy reduced the risk of major bleeding events or clinically relevant non-major bleeding events vs warfarin 
triple therapy regardless of proton pump inhibitor use, with comparable risk of the composite efficacy endpoint (all interaction 
p values > 0.05). For gastrointestinal bleeding, no interaction was observed between study treatment and proton pump inhibitor 
use (interaction p values 0.84 and 0.62 for dabigatran 110 and 150 mg dual therapy, respectively, vs warfarin triple therapy).
Conclusions Dabigatran 110 and 150 mg dual therapy reduced the risk of major bleeding events or clinically relevant non-
major bleeding events vs warfarin triple therapy, regardless of proton pump inhibitor use at baseline, in patients with atrial 
fibrillation who underwent percutaneous coronary intervention. Risk of the composite efficacy endpoint appeared to be 
similar for dabigatran dual therapy vs warfarin triple therapy in patients receiving/not receiving a proton pump inhibitor.
ClinicalTrials.gov unique identifier NCT02164864.
1 Introduction
Proton pump inhibitors (PPIs) are recommended for the pre-
vention of gastrointestinal (GI) bleeding in cardiovascular 
patients receiving antithrombotic therapy, especially in those 
with a higher risk of bleeding [1, 2]. Proton pump inhibitors 
reduce bleeding events when administered with aspirin [3] 
or clopidogrel [4]; however, results are conflicting on the 
interactions of PPIs with antiplatelet drugs and effects on 
clinical outcomes [5–7], and there are concerns regarding 
their cardiovascular safety [8, 9]. The Clopidogrel and the 
Optimization of Gastrointestinal Events Trial is the only ran-
domized study testing PPIs in patients taking dual antiplate-
let therapy (DAPT) with aspirin and clopidogrel and, despite 
the limitations of the trial (mainly the low number of events 
and the final reduced sample size), it suggested that use of 
omeprazole reduces upper GI bleeding in patients receiving 
DAPT, without an increase in cardiovascular events [10].
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Proton pump inhibitors are also expected to reduce 
the risk of GI bleeding in patients receiving oral antico-
agulation therapy, as suggested by observations in subjects 
treated with warfarin [11] and direct oral anticoagulants 
(DOACs) [12], including dabigatran [13]. Specifically, in 
patients with atrial fibrillation (AF) who underwent recent 
percutaneous coronary intervention (PCI), clinical prac-
tice guidelines recommend (except in patients with a very 
high risk of bleeding and a low risk of ischemic events) 
triple antithrombotic therapy with DAPT and an antico-
agulant agent. This regimen further increases the bleeding 
risk in this population [1, 2, 14]. Regarding dabigatran, a 
15% decrease in drug exposure by PPI use was found in 
the Randomized Evaluation of Long-term Anticoagulant 
Therapy (RE-LY) trial, without an observable impact on 
efficacy or safety [15].
The randomized RE-DUAL PCI trial compared dual 
antithrombotic therapy with dabigatran 110 or 150 mg 
twice daily (plus either clopidogrel or ticagrelor) with tri-
ple antithrombotic therapy with warfarin (plus aspirin and 
clopidogrel or ticagrelor) in patients with AF who under-
went PCI [16]. Dabigatran dual therapy reduced the risk of 
the primary endpoint of International Society on Thrombo-
sis and Haemostasis (ISTH)—defined major bleeding events 
(MBEs) or clinically relevant non-major bleeding events 
(CRNMBEs) vs warfarin triple therapy, and was non-inferior 
for the main clinical efficacy endpoint [16].
The effect of PPI administration in patients receiving both 
anticoagulant and antiplatelet therapies was not studied in 
the original publication, and it is not known whether the 
benefits in bleeding reduction with dabigatran dual therapy 
are valid both for patients taking and those not taking a PPI. 
This prespecified analysis of the RE-DUAL PCI trial was 
conducted to investigate whether PPI utilization at baseline 
could influence the main safety and efficacy results observed 
in the trial.
2  Methods
2.1  Patient Population
The RE-DUAL PCI trial (NCT02164864) was a prospec-
tive multicenter international study that randomized 2725 
patients to dabigatran dual therapy (plus clopidogrel or 
ticagrelor) or warfarin triple therapy (plus clopidogrel or 
ticagrelor and aspirin), including 1641 patients using PPIs 
at randomization. RE-DUAL PCI enrollment criteria, as 
well as the main trial results, have been published [16, 17]. 
Patients with paroxysmal, persistent, or permanent non-val-
vular AF who had undergone successful PCI in the previous 
120 hours were eligible. Main exclusion criteria were the 
presence of creatinine clearance < 30 mL/min, bioprosthetic 
or mechanical heart valve, or other major coexisting condi-
tions, such as cardiogenic shock during the current hospi-
talization, GI bleeding in the previous month, acute liver 
disease, or contraindication to oral anticoagulation and/or 
antiplatelet therapy with clopidogrel, ticagrelor, or aspirin.
Patients from the USA and those aged < 80 years (aged 
< 70 years in Japan) were randomized to dabigatran 110 or 
150 mg or warfarin in a 1:1:1 ratio. Patients outside the USA 
aged ≥ 80 years (aged ≥ 70 years in Japan) were randomized 
to the 110-mg dose of dabigatran vs warfarin in 1:1 ratio. 
In the warfarin triple-therapy group, aspirin was to be dis-
continued after 1 month in patients with a bare-metal stent 
implanted and after 3 months when a drug-eluting stent was 
implanted. All patients were to receive clopidogrel (75 mg 
once daily) or ticagrelor (90 mg twice daily) for ≥ 12 months 
after randomization; the choice of agent was left to the dis-
cretion of the investigator. Regarding PPI use, the study 
protocol stated: “The concomitant administration of PPI is 
strongly recommended in patients without clinical contrain-
dications for those agents, to reduce the risk of GI bleeding. 
In patients receiving clopidogrel, PPIs that do not interact 
with the CYP2C19 (lansoprazole, pantoprazole, etc.) should 
be used”.
For the present study, 2678 patients with complete data 
on PPI use at baseline (98.3% of the total randomized popu-
lation) were analyzed. The main objective of this prespeci-
fied subgroup analysis was to evaluate if PPI use influenced 
the treatment effect of dabigatran dual vs warfarin triple 
therapy on ISTH MBEs or CRNMBEs. Secondary objec-
tives included whether PPI use influenced the treatment 
effect of dabigatran dual vs warfarin triple therapy on ISTH 
MBEs, all GI bleeding, and all-cause mortality/thrombo-
embolic event (DTE) or unplanned revascularization (clini-
cal efficacy composite endpoint). A further objective was a 
treatment-independent evaluation (whole population), ana-
lyzing the influence of PPI utilization at baseline on bleeding 
and clinical efficacy composite endpoints.
Key Points 
The RE-DUAL PCI trial investigated patients with atrial 
fibrillation post-percutaneous coronary intervention. 
Dabigatran dual therapy (DDT) reduced bleeding risk vs 
warfarin triple therapy (WTT)
This subanalysis investigated patients categorized 
according to proton pump inhibitor use at baseline
Clinical efficacy endpoints were similar in DDT and 
WTT groups regardless of proton pump inhibitor use. 
DDT reduced bleeding risk vs WTT regardless of proton 
pump inhibitor use
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2.2  Statistical Analyses
Baseline characteristics of the population are summarized 
for patients taking/not taking PPIs. Continuous variables are 
depicted as means (standard deviations) and categorical vari-
ables as counts (percentages).
Cox proportional hazard regression models stratified by 
age (non-elderly or elderly; < 70 or ≥ 70 years in Japan 
and < 80 or ≥ 80 years elsewhere) were utilized to com-
pare dabigatran 110 mg dual therapy with warfarin triple 
therapy within PPI subgroup categories. Unstratified Cox 
proportional hazard regression models were utilized to com-
pare dabigatran 150 mg dual therapy with warfarin triple 
therapy excluding elderly patients outside the USA. Explora-
tory treatment by PPI subgroup interaction p values were 
derived from Cox proportional hazard regression models 
stratified by age for dabigatran 110 mg dual therapy vs war-
farin triple therapy and unstratified for dabigatran 150 mg 
dual therapy vs warfarin triple therapy. The same subgroup 
analysis was performed restricting the patient population to 
patients receiving clopidogrel at baseline.
Additionally, a multivariable adjusted Cox proportional 
hazard regression model was performed to compare treat-
ment groups including treatment and PPI use at baseline as 
a factor as well as the interaction between treatment and PPI 
use at baseline. For bleeding endpoints, this Cox model was 
adjusted for known bleeding risk factors: continuous varia-
bles, age, and creatinine clearance; and categorical variables, 
prior MBE or bleeding predisposition, prior GI bleeding or 
ulcerative GI disease or gastritis, diabetes mellitus, aspirin 
at baseline, modified HAS-BLED score at baseline (< 3 or 
≥ 3), previous stroke, indication for PCI (acute coronary 
syndrome or elective PCI), and ticagrelor use at baseline. 
For the clinical efficacy composite endpoint, this Cox model 
was adjusted for known risk factors of DTE: continuous var-
iables, age, and creatinine clearance; and categorical vari-
ables, prior myocardial infarction, diabetes, previous stroke, 
multi-vessel disease, indication for PCI, and ticagrelor use 
at baseline. The Cox model to compare dabigatran 110 mg 
dual therapy with warfarin triple therapy was stratified by 
age, whereas an unstratified Cox model was used to compare 
dabigatran 150 mg dual therapy with warfarin triple therapy.
To analyze the role of PPI utilization at baseline on 
clinical outcomes in the global population, a univariable, 
treatment-independent, Cox proportional hazard regres-
sion analysis stratified by age was developed (non-elderly 
vs elderly) including PPI use at baseline as the only fac-
tor in the model. A multivariable Cox proportional hazard 
regression analysis comparing risk of clinical outcomes 
between patients with and without PPI use at baseline was 
also performed. For bleeding endpoints, the Cox model was 
adjusted for the above-mentioned bleeding risk factors. For 
the clinical efficacy composite endpoint, the Cox model was 
adjusted for risk factors of all-cause mortality and thrombo-
embolic events.
All statistical analyses were two-sided and a p value 
< 0.05 was considered statistically significant. All p values 
are to be considered as exploratory. SAS 9.4 (SAS Institute 
Inc., Cary, NC, USA) was used for all statistical analyses.
3  Results
Of 2678 analyzed patients, 1641 (61.3%) used PPIs at 
baseline (Fig. 1 of the Electronic Supplementary Material 
[ESM]). Table 1 shows the characteristics of the popula-
tion. Patients taking PPIs comprised a higher-risk popula-
tion, being more frequently female and with a prior history 
of myocardial infarction, PCI, diabetes, hypertension, and 
GI bleeding. Mean  CHA2DS2-VASc and modified HAS-
BLED scores were similar between groups. Table 2 of the 
ESM shows the baseline characteristics of the population 
by PPI use and further split by treatment (i.e., eight groups). 
Regarding age, it is important to remember that patients out-
side the USA aged older than 79 years (aged older than 69 
years in Japan) were precluded to receive dabigatran 150 mg 
dual therapy. As can be seen in Fig. 2 of the ESM, the per-
centage of patients taking PPIs was stable during the follow-
up. For the 1641 patients taking PPIs at baseline, informa-
tion on PPI use at the end-of-treatment visit was missing for 
75 patients. Of the remaining 1566 patients, 1306 (83.4%) 
took PPIs at the end-of-treatment visit or since the last visit 
before the end of treatment. Of the 984 patients not using 
PPIs at baseline with available information at the end-of-
treatment visit, 23.1% were taking PPIs at the end-of-treat-
ment visit or since the last visit before the end of treatment 
(for 53 patients, information was missing at this visit).
3.1  Influence of Proton Pump Inhibitor Utilization 
at Baseline Regarding the Comparison 
of Dabigatran Dual vs Warfarin Triple Therapy
Dabigatran 110 and 150  mg dual therapy consistently 
reduced the risk of ISTH MBEs/CRNMBEs vs warfarin tri-
ple therapy regardless of PPI use, with a comparable risk for 
the composite efficacy endpoint.
Figure  1 shows the population receiving dabigatran 
110 mg dual therapy compared with warfarin triple therapy. 
Dabigatran 110 mg dual therapy considerably reduced the 
risk of bleeding events (ISTH MBE/CRNMBE, ISTH MBE 
alone) vs warfarin triple therapy, with a comparable risk of 
the clinical composite efficacy endpoint in both treatment 
groups, independent of PPI use at baseline (p values for 
interaction > 0.05).
Figure 2 analyzes the same parameters for the popula-
tion receiving dabigatran 150 mg dual therapy. The group 
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dabigatran dual therapy considerably reduced the risk of ISTH 
MBEs/CRNMBEs vs warfarin triple therapy with a compara-
ble risk of the clinical composite efficacy endpoint, independ-
ent of PPI utilization (p values for interaction > 0.05).
Figure 3 shows the additional endpoint of any GI bleed-
ing. No statistically significant interaction between treatment 
and PPI use at baseline was observed comparing dabigatran 
dual therapy with warfarin triple therapy (interaction p 
values 0.84 and 0.62 for dabigatran 110 and 150 mg dual 
therapy, respectively).
The results from multivariable-adjusted Cox models are 
similar to those in Figs. 1, 2 and 3 (p values for interaction 
> 0.05, Table 2). Importantly, the multivariable-adjusted 
hazard ratios of GI bleeding for dabigatran 110 mg dual 
therapy vs warfarin triple therapy were 0.82 (95% confi-
dence interval [CI] 0.42–1.59) for patients using PPIs and 
Table 1  Characteristics of the RE-DUAL PCI population: proton pump inhibitor (PPI) vs no PPI at baseline
Note, 47 patients with missing information on PPI use at baseline are excluded
ACE angiotensin converting enzyme, ACS acute coronary syndrome, CAD coronary artery disease, CrCl creatinine clearance, DES drug-eluting 
stent, GI gastrointestinal, LV left ventricular, MI myocardial infarction, PCI percutaneous coronary intervention, SD standard deviation, UFH 
unfractionated heparin
a Missing in 221 patients
b Missing in 183 patients
c Missing in one patient
d Missing in 20 patients
e Missing in 50 patients
f Missing in seven patients
PPI at baseline, yes PPI at baseline, no
Total (n = 1641) Total (n = 1037)
Demographic data
 Age, mean (SD), years 71.0 (8.7) 70.4 (8.6)
 Male sex, n (%) 1220 (74.3) 813 (78.4)
 CrCl, mL/min, mean (SD)a 76.5 (29.5) 80.5 (29.3)
Medical and surgical history
 Prior MI, n (%) 458 (27.9) 229 (22.1)
 Prior CAD, n (%) 1096 (66.8) 701 (67.6)
 Prior PCI, n (%) 585 (35.6) 311 (30)
 LV ejection fraction,b mean (SD), % 50.6 (12.3) 51.7 (12.8)
 Heart failure, n (%) 570 (34.7) 350 (33.8)
 Diabetes mellitus, n (%) 615 (37.5) 358 (34.5)
 Hypertension, n (%) 912 (55.6) 479 (46.2)
 Currently smoking,c n (%) 214 (13.0) 120 (11.6)
 Previous GI bleeding, ulcerative GI disease, or gastritis, n (%) 135 (8.2) 44 (4.2)
 Prior major bleeding or predisposition to bleeding, n (%) 18 (1.1) 13 (1.3)
 CHA2DS2-VASc score, mean (SD) 3.7 (1.6) 3.5 (1.6)
 Modified HAS-BLED score, mean (SD) 2.7 (0.7) 2.7 (0.7)
In-hospital approach
 Indication for PCI: ACS, n (%) 875 (53.3) 478 (46.1)
 Radial access,d n (%) 1054 (64.2) 649 (62.6)
 Only one coronary stent,e n (%) 1326 (80.8) 816 (78.7)
 Use of DES only,f n (%) 1367 (83.3) 843 (81.3)
 UFH use in index procedure, n (%) 1396 (85.1) 859 (82.8)
Baseline medications
 Clopidogrel, n (%) 1451 (88.4) 880 (84.9)
 Statins 1455 (88.7) 879 (84.8)
 Oral hypoglycemic drugs 430 (26.2) 255 (24.6)
 ACE inhibitors 912 (55.6) 497 (47.9)
 Angiotensin receptor blockers 535 (32.6) 334 (32.2)
 β-blockers 1387 (84.5) 844 (81.4)
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0.70 (95% CI 0.29–1.71) for those not using PPIs (p-inter-
action = 0.78); the hazard ratios for the comparison between 
dabigatran 150 mg dual therapy and warfarin triple therapy 
were, respectively, 0.83 (95% CI 0.36–1.91) and 0.71 (95% 
CI 0.25–2.06) [p-interaction = 0.81]. Table 1 of the ESM 
shows the same analyses as in Figs. 1, 2 and 3 but restricted 
to patients taking clopidogrel (87% of the population). Simi-
lar to that global population’s results, the p values obtained 
for interaction were all > 0.05. Specifically for GI bleeding, 
the p values for interaction were 0.61 for the comparison 
between dabigatran 110 mg dual therapy and warfarin tri-
ple therapy and 0.35 for the comparison between dabigatran 
150-mg dual therapy and warfarin triple therapy.
3.2  Influence of Proton Pump Inhibitor Utilization 
at Baseline on the Bleeding and Clinical Efficacy 
Composite Endpoint in the Whole Population 
(Study Treatment‑Independent Analysis)
In an additional analysis, we evaluated event rates for the 
whole population among patients treated or not treated 
with PPIs, by means of both univariable and multivariable 
models. The univariable analyses showed hazard ratios 
[HRs; 95% CIs of 1.00 (0.84–1.18), 1.12 (0.82–1.52), 
1.23 (0.81–1.89), and 1.20 (0.96–1.48)] for ISTH MBE/
CRNMBE, ISTH MBE alone, GI bleeding, and DTE/
unplanned revascularization, respectively. The multivaria-
ble-adjusted analyses showed similar results, with HRs (95% 
CIs) of 0.93 (0.78–1.12) for ISTH MBEs/CRNMBEs, 1.13 
(0.72–1.77) for GI bleeding, and 1.16 (0.92–1.45) for the 
clinical efficacy composite endpoint (Fig. 4).
4  Discussion
In this prespecified analysis of the RE-DUAL PCI trial 
[16] in patients with AF undergoing PCI, the benefit of 
dual antithrombotic therapy with dabigatran 110 or 150 mg 
twice daily in reducing the risk of MBEs or CRNMBEs, 
when compared with triple therapy with warfarin, did not 
appear to be influenced by use of a PPI at baseline. As such, 
dual therapy with both dosages of dabigatran did not seem 
to differ from warfarin triple therapy in terms of the risk 
of experiencing DTE or unplanned revascularization, also 
irrespective of PPI administration.
A meta-analysis comparing dual with triple antithrom-
botic therapy in 5317 patients from four randomized con-
trolled trials (including RE-DUAL PCI) showed that dual 
therapy led to lower risks of major or minor bleeding (HR, 
0.53; 95% CI 0.36–0.85) per Thrombolysis in Myocardial 
Infarction (TIMI) Study Group criterion, with comparable 
risk of major adverse cardiovascular events (HR 0.85; 95% 
Fig. 1  Safety and efficacy 
outcomes in patients receiv-
ing/not receiving proton pump 
inhibitors (PPIs) at baseline: 
dabigatran 110-mg dual therapy 
vs warfarin triple therapy. 
Hazard ratios (HRs) and 95% 
confidence interval (CIs) from 
the Cox proportional hazard 
model; stratified by age (elderly 
vs nonelderly). CRNMBE 
clinically relevant non-major 
bleeding event, DTE death/
thromboembolic event, ISTH 
International Society on Throm-
bosis and Haemostasis, MBE 
major bleeding event
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CI 0.48–1.29) [18]. More recently, a network meta-analysis 
of 10,026 patients from four trials (including RE-DUAL 
PCI) reported odds ratios for TIMI major bleeding of 0.49 
(95% CI 0.30–0.82) for DOAC plus a P2Y12 inhibitor, 
0.58 (95% CI 0.31–1.08) for a vitamin K antagonist plus a 
P2Y12 inhibitor, and 0.70 (95% CI 0.38–1.23) for DOAC 
plus DAPT, compared to a vitamin K antagonist plus DAPT 
as reference [19]. There was no significant difference in the 
risk of major adverse cardiovascular events [19].
To our knowledge, ours is the first study to investigate 
PPI use in patients receiving triple vs dual antithrombotic 
therapy with DOACs. In patients taking DAPT without 
anticoagulants, previous reports found that the use of PPIs 
significantly reduces the risk of GI bleeding [10, 20–22]. 
Similarly, a retrospective cohort analysis with patients using 
warfarin and aspirin suggested that PPI use was associ-
ated with a lower risk of upper GI bleeding hospitalization 
(adjusted HR 0.51; 95% CI 0.27–0.97), with a tendency of 
benefit for patients taking warfarin and a P2Y12 inhibitor 
(HR 0.54; 95% CI 0.29–1.01) [11]. In a large Medicare pop-
ulation taking an anticoagulant agent (very few with con-
comitant antiplatelet therapy), PPI use was associated with 
lower rates of hospitalization for upper GI bleeding when 
coadministered with both warfarin and DOACs, including 
dabigatran (incidence rate ratio for dabigatran: 0.49; 95% 
CI 0.41–0.59) [12].
The COMPASS trial analyzed > 17,000 patients rand-
omized to pantoprazole 40 mg daily or placebo on top of 
rivaroxaban and aspirin or monotherapy with each drug. In 
a 3-year follow-up, similar rates of the composite endpoint 
of cardiovascular deaths, myocardial infarction, or stroke 
were found for pantoprazole or the placebo groups [23]. The 
drug was generally well tolerated, with the exception of a 
significant 33% increase in the incidence of enteric infection. 
There were no significant differences between pantoprazole 
or placebo regarding upper GI events globally, or in other 
analyzed bleeding parameters, with the exception of “overt 
bleeding of GI origin confirmed by endoscopy of radiogra-
phy” (annual rate of 0.060% for pantoprazole vs 0.12% for 
placebo, p = 0.03) [24].
In the RE-LY trial, dabigatran 150 mg twice daily was 
associated with higher rates of GI bleeding compared with 
warfarin, which was not observed with dabigatran 110 mg 
[25]. Dabigatran is administered as a prodrug (dabigatran 
etexilate) and only 3–7% is absorbed into the systemic cir-
culation [26, 27]. The remaining non-absorbed prodrug may 
also undergo intraluminal activation by gut esterases, which 
may lead to bleeding owing to a topic effect on the intestinal 
mucosa [28, 29]. Conversely, bleeding events caused by anti-
platelet drugs and warfarin are observed mainly in the upper 
GI tract [10, 30]. Given these differences in anatomic sites of 
bleeding, PPIs would be expected to have a more significant 
Table 2  Safety and efficacy outcomes in patients receiving/not receiving proton pump inhibitors (PPIs) at baseline. Dabigatran dual therapy vs 
warfarin triple therapy: multivariable-adjusted analyses
CRNMBE clinically relevant non-major bleeding event, DTE death/thromboembolic event, GI gastrointestinal, HR hazard ratio, ISTH Interna-
tional Society on Thrombosis and Haemostasis, MBE major bleeding event
a See Sect. 2.2 for details
b For the comparison with dabigatran 150 mg dual therapy, elderly patients outside the USA are excluded
PPI at  
baseline
Dabigatran 
110 mg dual 
therapy n/N (%)
Warfarin triple 
therapy  
n/N (%)
HR (95%) Dabigatran 
150 mg dual 
therapy n/N (%)
Warfarin triple 
therapy  
n/N (%)b
HR (95%)
Adjudicated 
ISTH MBE/
CRNMB
PPI 89/549 (16.2) 137/527 (26.0) 0.64 (0.48–0.85) 82/417 (19.7) 106/405 (26.2) 0.75 (0.54–1.03)
No PPI 48/323 (14.9) 100/338 (29.6) 0.52 (0.36–0.74) 56/273 (20.5) 73/267 (27.3) 0.78 (0.54–1.13)
Interaction p 
value
0.3476 0.8640
Adjudicated 
ISTH MBE
PPI 31/549 (5.6) 45/527 (8.5) 0.73 (0.44–1.20) 22/417 (5.3) 32/405 (7.9) 0.65 (0.35–1.21)
No PPI 12/323 (3.7) 32/338 (9.5) 0.44 (0.22–0.88) 14/273 (5.1) 23/267 (8.6) 0.63 (0.31–1.28)
Interaction p 
value
0.2204 0.9228
Adjudicated GI 
bleeding
PPI 17/549 (3.1) 24/527 (4.6) 0.82 (0.42–1.59) 15/417 (3.6) 15/405 (3.7) 0.83 (0.36–1.91)
No PPI 8/323 (2.5) 15/338 (4.4) 0.70 (0.29–1.71) 7/273 (2.6) 9/267 (3.4) 0.71 (0.25–2.06)
Interaction p 
value
0.7792 0.8067
Adjudicated 
DTE/
unplanned 
revasculariza-
tion
PPI 93/544 (17.1) 71/520 (13.7) 1.25 (0.92–1.71) 54/413 (13.1) 56/398 (14.1) 0.96 (0.66–1.40)
No PPI 43/327 (13.1) 45/332 (13.6) 0.95 (0.62–1.44) 27/269 (10.0) 30/265 (11.3) 0.92 (0.54–1.55)
Interaction p 
value
0.2877 0.8954
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role in bleeding prevention for patients treated with war-
farin triple therapy than patients receiving dabigatran dual 
therapy. Nevertheless, contrary to this rationale, our analysis 
suggests that, even when receiving a PPI, patients in the 
warfarin triple-therapy group did not show lower GI bleed-
ing rates than patients prescribed dabigatran dual therapy, 
with a numerically lower risk for patients utilizing PPIs with 
dabigatran 110 mg dual therapy, in comparison with warfa-
rin triple therapy plus PPIs (HR of 0.66).
Regarding clinical efficacy (DTE/unplanned revasculari-
zation), PPIs may reduce absorption of dabigatran [31, 32], 
and concerns have been raised that PPIs could reduce the 
Fig. 2  Safety and efficacy 
outcomes in patients receiv-
ing/not receiving proton pump 
inhibitors (PPIs) at baseline: 
dabigatran 150 mg dual therapy 
vs warfarin triple therapy. For 
the comparison with 150 mg 
dabigatran dual therapy, elderly 
patients outside the USA are 
excluded. Hazard ratios (HRs) 
and 95% confidence intervals 
(CIs) from the unstratified Cox 
proportional hazard model. 
CRNMBE clinically relevant 
non-major bleeding event, DTE 
death/thromboembolic event, 
ISTH International Society on 
Thrombosis and Haemostasis, 
MBE major bleeding event
Fig. 3  Gastrointestinal bleed-
ing in patients receiving/
not receiving proton pump 
inhibitors (PPIs) at baseline: 
dabigatran 110 mg and 150 mg 
dual therapy vs warfarin triple 
therapy. For the comparison 
with 150 mg dabigatran dual 
therapy, elderly patients outside 
the USA are excluded. Statistics 
as in Figs. 1 and 2, respectively. 
CI confidence interval, HR 
hazard ratio
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conversion of clopidogrel (the most commonly used P2Y12 
inhibitor in RE-DUAL: 87%) into its active metabolite, [31] 
despite that in RE-DUAL the benefits of dabigatran 110 mg 
or 150 mg dual therapy in comparison with warfarin triple 
therapy in decreasing bleeding risks were consistent across 
patients treated with clopidogrel or ticagrelor. [33] Proton 
pump inhibitors could also have a deleterious impact in vas-
cular function per se [9]. All these theoretical effects could 
eventually lead to a higher incidence of clinical efficacy end-
points in patients treated with a PPI [4, 34, 35].
In the present study, in the dabigatran 110-mg subgroup, a 
HR of 1.30 was observed for patients taking PPIs vs not tak-
ing PPIs, but this trend was not observed in the dabigatran 
150-mg subgroup. Thus, no consistent difference between 
treatment groups was seen. However, despite that no signifi-
cant interactions were observed in the subgroup of patients 
taking clopidogrel, a HR of 1.45 was observed in the popula-
tion on dabigatran 110 mg, but this trend was not observed 
in the dabigatran 150 mg subgroup; this finding could be 
related to an interaction between PPI and clopidogrel [7], 
leading to an increase in clinical events in the dabigatran 
110 mg subgroup that was blunted with the dabigatran 
150 mg doses. However, we urge caution because this one 
finding is in a subgroup of a subgroup, and the interaction p 
value is not statistically significant, thus indicating that this 
cannot be determined from this dataset.
4.1  Limitations
Our results should be interpreted in the context of a sub-
group analysis of a randomized trial in a setting with very 
few data available from other sources. The RE-DUAL PCI 
trial was not powered for any subgroup analysis and no 
adjustment for multiplicity was performed, thus the reported 
results should be regarded as exploratory. As in all publica-
tions with similar characteristics, there are imbalances in the 
baseline characteristics of patients taking vs not taking PPIs, 
and differences in baseline characteristics were previously 
acknowledged as a possible source of bias when analyzing 
the effect of PPI therapy on cardiovascular outcomes [4]. 
Second, we did not have information about the time using 
a PPI during follow-up, which may limit assessment of the 
influence of PPI intake on long-term bleeding and cardio-
vascular outcomes. Third, more granular data regarding PPI 
brand and dosage were not available, limitations that are 
shared with similar analyses [12]. Finally, we did not retrieve 
information about upper vs lower GI bleeding, which could 
be useful to better understand potential interactions between 
PPIs, DOAC use, and bleeding.
5  Conclusions
Dual therapy with dabigatran at both 110- and 150-mg doses 
twice daily reduced the risk of bleeding when compared 
with warfarin triple therapy, regardless of PPI use at baseline 
in patients with AF undergoing PCI. The risk of clinical effi-
cacy endpoints appeared similar with dabigatran dual ther-
apy vs warfarin triple therapy irrespective of PPI utilization.
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